New Aspects in Descriptive, Etiologic, and Molecular Epidemiology of Hodgkin's Lymphoma

Hematology/Oncology Clinics of North America

Volumn 21, Issue 5, 2007, Pages 825-840

  Landgren, Ola ^a   Caporaso, Neil E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DESCRIPTIVE RESEARCH; DRUG DOSE ESCALATION; EPSTEIN BARR VIRUS; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; METASTASIS; MOLECULAR EPIDEMIOLOGY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REED STERNBERG CELL; REVIEW; SEX RATIO;

AGE FACTORS; CHINA; EMIGRATION AND IMMIGRATION; EPIDEMIOLOGY, MOLECULAR; EPSTEIN-BARR VIRUS INFECTIONS; HODGKIN DISEASE; HUMANS; SEX FACTORS; WORLD HEALTH;

EID: 34848842754     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.07.001     Document Type: Review

References (107)

1. Hodgkin T. On some morbid experiences of the absorbent glands and spleen. Med Chir Trans 17 (1832) 69-97
2. Wilks S. Cases of enlargement of the lymphatic glands and spleen (or Hodgkin's disease), with remarks. Guy's Hosp Rep 11 (1865) 56-67
3. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
4. Parkin D.M., Whelan S.L., Ferlay J., et al. Cancer incidence in five continents vol. I to VIII (2005), IARC, Lyon CancerBase No. 7
5. Ries L.A.G., Harkins D., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2003 (2006), National Cancer Institute, Bethesda, (MD)
6. O'Grady J., Stewart S., Elton R.A., et al. Epstein-Barr virus in Hodgkin's disease and site of origin of tumour. Lancet 343 8892 (1994) 265-266
7. Diepstra A., Niens M., Vellenga E., et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 365 9478 (2005) 2216-2224
8. Biggar R.J., Jaffe E.S., Goedert J.J., et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108 12 (2006) 3786-3791
9. Bierman P.J., Vose J.M., Langnas A.N., et al. Hodgkin's disease following solid organ transplantation. Ann Oncol 7 3 (1996) 265-270
10. Rowlings P.A., Curtis R.E., Passweg J.R., et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol 17 10 (1999) 3122-3127
11. Landgren O., Engels E.A., Pfeiffer R.M., et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 98 18 (2006) 1321-1330
12. Goldgar D.E., Easton D.F., Cannon-Albright L.A., et al. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86 21 (1994) 1600-1608
13. Goldin L.R., Pfeiffer R.M., Gridley G., et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 100 9 (2004) 1902-1908
14. Lindelof B., and Eklund G. Analysis of hereditary component of cancer by use of a familial index by site. Lancet 358 9294 (2001) 1696-1698
15. Paltiel O., Schmit T., Adler B., et al. The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study. Cancer 88 10 (2000) 2357-2366
16. Shugart Y.Y., Hemminki K., Vaittinen P., et al. A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. Hum Genet 106 5 (2000) 553-556
17. Westergaard T., Melbye M., Pedersen J.B., et al. Birth order, sibship size and risk of Hodgkin's disease in children and young adults: a population-based study of 31 million person-years. Int J Cancer 72 6 (1997) 977-981
18. Au W.Y., Gascoyne R.D., Gallagher R.E., et al. Hodgkin's lymphoma in Chinese migrants to British Columbia: a 25-year survey. Ann Oncol 15 4 (2004) 626-630
19. Seow A., Koh W.P., Chia K.S., et al. Trends in cancer incidence in Singapore 1968-2002 (2004), Singapore Cancer Registry, Singapore p. 6
20. Jackson J., and Parker J. Hodgkin's disease and allied disorders (1947), Oxford University Press, New York
21. Harris N.L. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol 36 3 (1999) 220-232
22. Smetana H.F., and Cohen B.M. Mortality in relation to histologic type in Hodgkin's disease. Blood 11 3 (1956) 211-224
23. Rosenthal S. Significance of tissue lymphocytes in the prognosis of lymphogranulomatosis. Arch Pathol 21 (1936) 628-646
24. Lukes R.J. Relationship of histologic features to clinical stages in Hodgkin's disease. Am J Roentgenol Radium Ther Nucl Med 90 (1963) 944-955
25. Lukes R.J., and Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 26 6 (1966) 1063-1083
26. Harris N.L., Jaffe E.S., Diebold J., et al. Lymphoma classification-from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 11 Suppl 1 (2000) 3-10
27. Cossman J., Annunziata C.M., Barash S., et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 94 2 (1999) 411-416
28. Brauninger A., Hansmann M.L., Strickler J.G., et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 340 16 (1999) 1239-1247
29. Kuppers R., Roers A., and Kanzler H. Molecular single cell studies of normal and transformed lymphocytes. Cancer Surv 30 (1997) 45-58
30. Marafioti T., Hummel M., Anagnostopoulos I., et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337 7 (1997) 453-458
31. Marafioti T., Hummel M., Foss H.D., et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95 4 (2000) 1443-1450
32. Braeuninger A., Kuppers R., Strickler J.G., et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 94 17 (1997) 9337-9342
33. Falini B., and Mason D.Y. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 99 2 (2002) 409-426
34. Carbone A., Gloghini A., Gaidano G., et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 92 7 (1998) 2220-2228
35. Falini B., Bigerna B., Pasqualucci L., et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 87 2 (1996) 465-471
36. Muschen M., Rajewsky K., Brauninger A., et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 191 2 (2000) 387-394
37. Seitz V., Hummel M., Marafioti T., et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95 10 (2000) 3020-3024
38. Anonymous. Cancer facts & figures 2007 (2007), American Cancer Society, Atlanta (GA)
39. Perkins C.I., Morris C.R., Wright W.E., et al. Cancer incidence and mortality in California by detailed race/ethnicity, 1988-1992 (1995), California Department of Health Services Surveillance Section, Sacramento (CA)
40. Kennedy B.J., Fremgen A.M., and Menck H.R. The National Cancer Data Base report on Hodgkin's disease for 1985-1989 and 1990-1994. Cancer 83 5 (1998) 1041-1047
41. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21 4 (2003) 607-614
42. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 21 (1992) 1478-1484
43. Diehl V., and Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?. Cancer Invest 24 7 (2006) 713-717
44. Forsyth P.D., Bessell E.M., Moloney A.J., et al. Hodgkin's disease in patients older than 70 years of age: a registry-based analysis. Eur J Cancer 33 10 (1997) 1638-1642
45. Eghbali H., Hoerni-Simon G., de Mascarel I., et al. Hodgkin's disease in the elderly. A series of 30 patients aged older than 70 years. Cancer 53 10 (1984) 2191-2193
46. Wedelin C., Bjorkholm M., Biberfeld P., et al. Prognostic factors in Hodgkin's disease with special reference to age. Cancer 53 5 (1984) 1202-1208
47. Landgren O. Diagnostic and prognostic studies in Hodgkin's lymphoma (2002), Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm
48. Westling P. Studies of the prognosis in Hodgkin's disease. Acta Radiol Suppl 245 (1965) 5-125
49. Landgren O., Algernon C., Axdorph U., et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88 4 (2003) 438-444
50. Engert A., Ballova V., Haverkamp H., et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23 22 (2005) 5052-5060
51. Ballova V., Ruffer J.U., Haverkamp H., et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16 1 (2005) 124-131
52. Weekes C.D., Vose J.M., Lynch J.C., et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20 4 (2002) 1087-1093
53. Proctor S.J., White J., and Jones G.L. An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme. Eur J Haematol Suppl 66 (2005) 63-67
54. Landgren O., Axdorph U., Fears T.R., et al. A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients. Ann Oncol 17 8 (2006) 1290-1295
55. van Spronsen D.J., Janssen-Heijnen M.L., Breed W.P., et al. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 78 7 (1999) 315-319
56. Erdkamp F.L., Breed W.P., Bosch L.J., et al. Hodgkin disease in the elderly. A registry-based analysis. Cancer 70 4 (1992) 830-834
57. Peterson B.A., Pajak T.F., Cooper M.R., et al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 66 4 (1982) 889-898
58. Levis A., Depaoli L., Bertini M., et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 81 5 (1996) 450-456
59. Specht L., and Nissen N.I. Hodgkin's disease and age. Eur J Haematol 43 2 (1989) 127-135
60. Correa P., and O'Conor G.T. Epidemiologic patterns of Hodgkin's disease. Int J Cancer 8 2 (1971) 192-201
61. Macfarlane G.J., Evstifeeva T., Boyle P., et al. International patterns in the occurrence of Hodgkin's disease in children and young adult males. Int J Cancer 61 2 (1995) 165-169
62. Aozasa K., Ueda T., Tamai M., et al. Hodgkin's disease in Osaka, Japan (1964-1985). Eur J Cancer Clin Oncol 22 9 (1986) 1117-1119
63. Clarke C.A., and Glaser S.L. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94 7 (2002) 2015-2023
64. Ng A.K., Bernardo M.V., Weller E., et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100 6 (2002) 1989-1996
65. Dores G.M., Metayer C., Curtis R.E., et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20 16 (2002) 3484-3494
66. Ng A.K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20 8 (2002) 2101-2108
67. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 18 (2003) 3431-3439
68. Hoppe R.T. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 8 Suppl 1 (1997) 115-118
69. Travis L.B., Hill D.A., Dores G.M., et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290 4 (2003) 465-475
70. van Leeuwen F.E., Klokman W.J., Stovall M., et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 13 (2003) 971-980
71. Hill D.A., Gilbert E., Dores G.M., et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 106 10 (2005) 3358-3365
72. Travis L.B., Hill D., Dores G.M., et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97 19 (2005) 1428-1437
73. Foss Abrahamsen A., Andersen A., Nome O., et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 13 11 (2002) 1786-1791
74. Aleman B.M., van den Belt-Dusebout A.W., De Bruin M.L., et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109 5 (2007) 1878-1886
75. Hjalgrim H., Askling J., Sorensen P., et al. Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 92 18 (2000) 1522-1528
76. Mueller N.E. Hodgkin's disease. In: Schottenfield D., and Fraumeni Jr. J.F. (Eds). Cancer epidemiology and prevention. 2nd edition (1996), Oxford University Press, New York 893-919
77. Tomita Y., Ohsawa M., Kanno H., et al. Epstein-Barr virus in Hodgkin's disease patients in Japan. Cancer 77 1 (1996) 186-192
78. Alexander F.E., Jarrett R.F., Lawrence D., et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer 82 5 (2000) 1117-1121
79. Sleckman B.G., Mauch P.M., Ambinder R.F., et al. Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection. Cancer Epidemiol Biomarkers Prev 7 12 (1998) 1117-1121
80. Glaser S.L., Lin R.J., Stewart S.L., et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 70 4 (1997) 375-382
81. Gallagher A., Perry J., Freeland J., et al. Hodgkin lymphoma and Epstein-Barr virus (EBV): no evidence to support hit-and-run mechanism in cases classified as non-EBV-associated. Int J Cancer 104 5 (2003) 624-630
82. Benharroch D., Shemer-Avni Y., Levy A., et al. New candidate virus in association with Hodgkin's disease. Leuk Lymphoma 44 4 (2003) 605-610
83. Goedert J.J., Cote T.R., Virgo P., et al. Spectrum of AIDS-associated malignant disorders. Lancet 351 9119 (1998) 1833-1839
84. Carbone A., and Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 130 5 (2005) 662-670
85. Klippel J.H. Primer on the rheumatic diseases. 12th edition (2001), Arthritis Foundation, Atlanta (GA)
86. Bjornadal L., Lofstrom B., Yin L., et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31 2 (2002) 66-71
87. Kassan S.S., Thomas T.L., Moutsopoulos H.M., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89 6 (1978) 888-892
88. Isomaki H.A., Hakulinen T., and Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31 11 (1978) 691-696
89. Mellemkjaer L., Andersen V., Linet M.S., et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40 4 (1997) 761-768
90. Gridley G., McLaughlin J.K., Ekbom A., et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85 4 (1993) 307-311
91. Ekstrom K., Hjalgrim H., Brandt L., et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 48 4 (2003) 963-970
92. Thomas E., Brewster D.H., Black R.J., et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88 3 (2000) 497-502
93. Mellemkjaer L., Alexander F., and Olsen J.H. Cancer among children of parents with autoimmune diseases. Br J Cancer 82 7 (2000) 1353-1357
94. Hartge P., and Wang S.S. Overview of the etiology and epidemiology of lymphoma. In: Mauch P., Armitage J., Lee N., Dalla-Favera R., and Coiffier B. (Eds). Non-Hodgkin's lymphoma (2004), Lippincott Williams & Wilkins, Philadelphia
95. Landgren O., Kerstann K.F., Gridley G., et al. Re: Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 97 7 (2005) 543-544
96. Smedby K.E., Hjalgrim H., Askling J., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98 1 (2006) 51-60
97. Engels E.A., Cerhan J.R., Linet M.S., et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 162 12 (2005) 1153-1161
98. Zintzaras E., Voulgarelis M., and Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165 20 (2005) 2337-2344
99. Penn I. Neoplastic complications of transplantation. Semin Respir Infect 8 3 (1993) 233-239
100. Haluska F.G., Brufsky A.M., and Canellos G.P. The cellular biology of the Reed-Sternberg cell. Blood 84 4 (1994) 1005-1019
101. Garnier J.L., Lebranchu Y., Lefrancois N., et al. Hodgkin's disease after renal transplantation. Transplant Proc 27 2 (1995) 1785
102. Goldin L.R., McMaster M.L., Ter-Minassian M., et al. A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. J Med Genet 42 7 (2005) 595-601
103. Glaser S.L. Reproductive factors in Hodgkin's disease in women: a review. Am J Epidemiol 139 3 (1994) 237-246
104. Kravdal O., and Hansen S. The importance of childbearing for Hodgkin's disease: new evidence from incidence and mortality models. Int J Epidemiol 25 4 (1996) 737-743
105. Kravdal O., and Hansen S. Hodgkin's disease: the protective effect of childbearing. Int J Cancer 55 6 (1993) 909-914
106. Swerdlow A., dos Santos Silva I., and Doll R. Cancer incidence and mortality in England and Wales: trends and risk factors (2001), Oxford University Press, Oxford (UK)
107. McCunney R.J. Hodgkin's disease, work, and the environment. A review. J Occup Environ Med 41 1 (1999) 36-46